Navigation Links
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
Date:2/19/2010

DUBLIN, February 19, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the year to December 31, 2009.

    Financial Highlights

                                     Full Year 2009(1)        Q4 2009(1)
    Product sales                  $2,694 million     -2% $777 million   +10%
    Product sales from core
    products(2)                    $2,067 million    +25% $585 million   +36%
    Total revenues                 $3,008 million      0% $893 million   +17%
    Non GAAP operating income        $889 million     -7% $313 million   +30%
    US GAAP operating income         $620 million    +51% $268 million   +39%
    Non GAAP diluted earnings per
    ADS                                     $3.49    -10%        $1.11    +9%
    US GAAP diluted earnings per
    ADS                                     $2.69   +214%        $0.94   +20%

These results include the effect of a change in best estimate of the Medicaid rebate liability for ADDERALL XR, which increased fourth quarter product sales by $98 million, and fourth quarter Non GAAP diluted earnings per American Depositary Share ("ADS") by 32 cents. Product sales excluding this change in best estimate would have been $2,596 million for the year to December 31, 2009 and $679 million for the fourth quarter. Non GAAP diluted earnings per ADS excluding this change in best estimate would have been $3.17 for the year to December 31, 2009 and 79 cents for the fourth quarter. For further details see pages 9 to 10 and 26.

(1) Percentages compare to equivalent 2008 periods.

(2) Core products represent Shire's products excluding ADDERALL XR.

Angus Russell, Chief Executive Officer, commented:

"In this challenging and transformational year for Shire, I believe these excellent results reflect the success of our focused strategy and business model.

Strong fourth quarter sales growth of 36% from our core product portfolio, supported by our increasing international reach, has contributed significantly to our full year Non GAAP diluted earnings per ADS of $3.49. Our recent decision to lower our best estimate of the Medicaid sales rebates for ADDERALL XR contributed 32 cents to these earnings, which was not previously anticipated in our guidance framework.

Our growth prospects remain excellent and our core product portfolio currently has robust exclusivity protection. We have launched INTUNIV successfully in the US, we plan to launch velaglucerase alfa (VPRIV) imminently, and there is also an opportunity for REPLAGAL to enter the US market. We have already seen encouraging signs for the future success of these three products. REPLAGAL has increased its share in ex-US markets and we expect this momentum to increase.

VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and has recently been launched in Canada. ADDERALL XR continues to generate value from both product sales and a considerable royalty stream.

We have also demonstrated a pro-active approach to cost management in 2009 as promised, and have the opportunity to leverage our existing infrastructure to deliver expanding margins in the future. We enter 2010 with a strong balance sheet and excellent cash generation. This will allow us to continue to expand our international presence and consider potential acquisitions and in-licensing opportunities that fit our strategy.

We look forward to growing revenues and earnings in 2010 and re-iterate our aspirational target of mid-teen revenue growth on average between 2009 and 2015."

    FINANCIAL SUMMARY
    Full Year 2009 Unaudited Results

                     Full Year 2009                  Full Year 2008
                                       Non                             Non
            US GAAP   Adjustments     GAAP  US GAAP   Adjustments     GAAP
                 $M            $M       $M       $M            $M       $M
    Revenues  3,008             -    3,008    3,022             -    3,022
    Operating
    income      620           269      889      412           546      958
    Diluted
    earnings
    per ADS   $2.69         $0.80    $3.49    $0.86         $3.00    $3.86

These results include the effect of a change in best estimate of the Medicaid rebate liability for ADDERALL XR, which increased product sales by $98 million, and Non GAAP diluted earnings per ADS by 32 cents. Revenues and Non GAAP diluted earnings per ADS excluding this change in best estimate for the year to December 31, 2009 would have been $2,910 million and $3.17 respectively. For further details see pages 9-10 and 26.

The Non GAAP financial measures included in the tables above are explained on pages 27 and 28, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 22 to 23 and 26 (full year) and pages 24 to 26 (Q4).

    - Product sales from core products were up 25% to $2,067 million (2008:
      $1,653 million). On a constant exchange rate ("CER") basis, which is a
      Non GAAP measure, core product sales were up 28% driven by continued
      strong growth from:

      - VYVANSE(R) (up 58% to $505 million, CER: up 58%);
      - LIALDA(R) / MEZAVANT(R) (up 68% to $236 million, CER: up 69%);
      - ELAPRASE(R) (up 16% to $353 million, CER: up 20%); and
      - REPLAGAL(R) (up 10% to $194 million, CER: up 16%).

    - Product sales including ADDERALL XR(R) were down 2% to $2,694 million
      (CER: 0%), due to the expected decline in ADDERALL XR product sales
      ($627 million, down 43% on 2008) following the launch of authorized
      generic versions by Teva Pharmaceuticals USA Inc. ("Teva") in April
      2009 and Impax Laboratories Inc. ("Impax") in October 2009, with the
      strong performance from Shire's core products (up 25%) offsetting the
      decrease in ADDERALL XR product sales.

    - Revenues for the year to December 31, 2009 decreased marginally to
      $3,008 million (2008: $3,022 million), as the 25% increase in core
      product sales and royalty income received on Teva and Impax's sales of
      authorized generic ADDERALL XR offset the decline in ADDERALL XR
      product sales.

    - Non GAAP operating income decreased by 7%, or $69 million, to $889
      million as a result of the marginally lower revenues and Shire's
      increased investment in research and development in 2009, which were
      partially offset by lower selling, general and administrative costs
      from Shire's continued focus on cost management. On a US GAAP basis,
      operating income in 2009 was $620 million, compared to $412 million in
      2008, an increase of 51% (2008 included in-process R&D ("IPR&D")
      charges of $263 million related to the acquisitions of Jerini AG
      ("Jerini") and METAZYM).

    - Non GAAP diluted earnings per ADS were down 10% to $3.49 (2008: $3.86).
      On a US GAAP basis diluted earnings per ADS increased to $2.69 compared
      to $0.86 in 2008, up 214% (earnings in 2008 were impacted by interest
      charges on the Transkaryotic Therapies Inc. ("TKT") appraisal rights
      settlement, IPR&D and other impairment charges, all of which reduced US
      GAAP diluted earnings per ADS in 2008).

    - Cash generation, which is a Non GAAP measure, in 2009 was $921 million
      (2008: $1,231 million), a decrease of $310 million. Cash generation was
      lower in 2009 due to lower net sales receipts following the
      genericization of ADDERALL XR. Cash generation in 2008 also included
      cash inflows from forward exchange contracts which were not repeated in
      2009.

2010 OUTLOOK

We enter 2010 with good momentum driven by the growth of our core product portfolio. 2010 will also benefit from the change in best estimate for ADDERALL XR rebates implemented in the fourth quarter of 2009 against a background of further erosion of the brand and the impact of adverse business mix trends.

In the first quarter of 2010 we expect our total revenues and Non GAAP diluted earnings per ADS to be lower than the same period in 2009, which was the last quarter before ADDERALL XR faced generic competition. For the balance of the year Shire expects to generate both total revenue growth and Non GAAP diluted earnings per ADS growth compared to 2009.

During 2010 we expect to see gross margins as a percentage of product sales at a similar level to 2009. We will further increase our focused investment in R&D and targeted investment will increase SG&A year on year. We expect a Non GAAP effective tax rate in 2010 at a similar level to 2009.

We look forward to growing both total revenues and reported Non GAAP diluted earnings per ADS in the full year 2010 compared to the excellent 2009 Non GAAP results and re-iterate our aspirational target of mid-teen revenue growth on average between 2009 and 2015.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, product launches in 2010 will include:

    - VPRIV(TM) for the treatment of Gaucher disease in the US and
      EU;
    - REPLAGAL for the treatment of Fabry disease in the US;
    - MEZAVANT for the treatment of ulcerative colitis in certain
      EU and RoW countries;
    - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary
      angiodema in certain European and Latin American countries;
    - EQUASYM(R) for the treatment of ADHD in certain EU
      countries; and
    - VYVANSE for the treatment of ADHD in Canada.


    Fourth Quarter 2009 Unaudited Results

                           Q4 2009                         Q4 2008
                                          Non                             Non
               US GAAP   Adjustments     GAAP  US GAAP   Adjustments     GAAP
                    $M            $M       $M       $M            $M       $M
    Revenues       893             -      893      766             -      766
    Operating
    income         268            45      313      193            48      241

    Diluted
    earnings
    per ADS      $0.94         $0.17    $1.11    $0.78         $0.23    $1.01

These results include the effect of a change in best estimate of the Medicaid rebate liability for ADDERALL XR, which increased product sales by $98 million, and Non GAAP diluted earnings per ADS by 32 cents. Revenues and Non GAAP diluted earnings per ADS excluding this change in best estimate for the fourth quarter would have been $795 million and 79 cents respectively. For further details see pages 9 to 10 and 26.

The Non GAAP financial measures included above are explained on pages 27 and 28, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 24 to 26.

    - Product sales from core products were up 36% (CER: up 32%) to $585
      million (2008: $429 million) following continued growth from VYVANSE,
      LIALDA/MEZAVANT, ELAPRASE and REPLAGAL.

    - Product sales including ADDERALL XR, increased by 10% to $777 million
      (CER: up 8%). In Q4 2009 ADDERALL XR sales included the effect of a
      change in best estimate of the amount of Medicaid rebate payable on
      sales of ADDERALL XR. The effect of this change in best estimate
      increased ADDERALL XR net product sales for Q4 2009 by $98 million, of
      which $74 million related to product sales recognized in Q1 - Q3 2009.
      Q4 product sales, excluding the effect of the change in best estimate
      relating to product sales recognized in Q1 - Q3 2009, declined
      marginally to $703 million (2008: $704 million).

    - Revenues in Q4 2009 increased by 17% to $893 million (2008: $766
      million). The decline in ADDERALL XR product sales following
      genericization was more than offset by strong core product sales growth
      and royalty income on Impax's sales of authorized generic ADDERALL XR.

    - Non GAAP operating income increased by 30%, or $72 million, to $313
      million as the higher product sales and royalty income were only
      partially offset by increased investment in research and development.
      On a US GAAP basis operating income in Q4 2009 increased 39%, or $75
      million to $268 million (2008: $193 million).

    - Non GAAP diluted earnings per ADS for Q4 2009 were up 9% to $1.11 (Q4
      2008: $1.01). On a US GAAP basis diluted earnings per ADS were up 20%
      to $0.94 (2008: $0.78).


    FOURTH QUARTER 2009 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS
    Products

    VYVANSE - for the treatment of ADHD

    - On February 1, 2010 Shire announced the Canadian
      availability of VYVANSE (lisdexamfetamine dimesylate capsule), the
      first and only prodrug therapy approved for ADHD treatment in Canada.

    INTUNIV - for the treatment of ADHD in children and adolescents in the US

    - Once-daily INTUNIV became available in US pharmacies on
      November 9, 2009 and comes in four dosage strengths (1 mg, 2 mg, 3 mg,
      and 4 mg). INTUNIV is marketed in the US by the existing Shire ADHD
      sales team of nearly 600 representatives.

    - Revenue on the launch shipments of INTUNIV has been deferred
      and is being recognised in line with prescription demand. On this
      basis, INTUNIV achieved sales of $5.4 million from launch through
      December 31, 2009.

    DAYTRANA - for the treatment of ADHD in adolescents in the US

    - On December 4, 2009 and on January 29, 2010 Shire issued a
      voluntary recall of certain lots of DAYTRANA because some of the
      patches do not meet, or in future may not meet, their release liner
      removal specification, and as a result, patients and caregivers could
      have difficulty removing the liners. This action was not due to any
      safety issues and no interruption in product supply is anticipated.

    Pipeline

    VPRIV - for the treatment of Type 1 Gaucher disease

    - On November 24, 2009 Shire submitted a marketing authorization
      application to the European Medicines Agency ("EMEA") for VPRIV,
      Shire's enzyme replacement therapy in development for the treatment of
      Type 1 Gaucher disease. The submission has been granted an accelerated
      review by EMEA. Submissions have also been made in the US on September
      1, 2009 and Canada on October 20, 2009. In the U.S., the application is
      being reviewed by the US Food and Drug Administration ("FDA") under
      Priority Review with a Prescription Drug User Fee Act action date of
      February 28, 2010. The FDA recently completed pre-approval inspections
      of Shire's Massachusetts facilities for the manufacturing and testing
      of VPRIV. These inspections were an important milestone in the review
      and approval process for the VPRIV New Drug Application.

    - VPRIV is available ahead of its commercial launch in the US via an
      FDA-accepted treatment protocol and elsewhere on a pre-approval basis
      using the fastest mechanisms available in each country, in response to
      the ongoing shortage of a currently marketed treatment for Type 1
      Gaucher disease.

    - Pending FDA approval, Shire intends to price the VPRIV 400 Unit vial at
      a wholesale acquisition cost ("WAC") of $1,350 in the US.

    - We are pleased to announce enhancements to our OnePathSM Access
      program. In addition to our existing patient assistance programs and
      our support of patient associations, Shire will provide direct co-pay
      assistance, covering the first 3 months of out-of-pocket prescription
      costs for eligible US patients this year. In 2011, we also plan to cap
      the out-of-pocket prescription costs for these patients at $500. This
      new program will be effective March 1, 2010 for eligible ELAPRASE
      patients and VPRIV patients pending FDA approval.

    VYVANSE - for the treatment of ADHD

    - On December 21, 2009 a supplemental New Drug Submission for VYVANSE was
      submitted in Canada for the extension of the indication to adolescents
      and adults with ADHD.

    - On January 14, 2010 a supplemental New Drug Application for VYVANSE was
      submitted to the FDA for the extension of the indication to adolescents
      aged 13 to 17 years with ADHD.

    REPLAGAL - for the treatment of Fabry disease

    - On December 22, 2009 Shire submitted a Biologics License Application to
      the FDA for REPLAGAL, its enzyme replacement therapy for Fabry disease.
      Shire has worked closely with the FDA to establish an early access
      program in response to the ongoing shortage of the currently marketed
      treatment for Fabry disease in the US. REPLAGAL is currently available
      to Fabry patients in the US under an FDA-approved treatment protocol,
      and Shire is also supporting emergency Investigational New Drug
      requests. REPLAGAL first received marketing authorization in the
      European Union in 2001, and is approved for the treatment of Fabry
      disease in 45 countries. Shire expects its REPLAGAL supply to be
      adequate to meet anticipated global demand.

    OTHER FOURTH QUARTER AND RECENT DEVELOPMENTS

    - On December 23, 2009 Shire completed the purchase of the remaining
      Jerini shares from the minority shareholders, and now owns 100% of
      Jerini.

    - On February 24, 2009 Actavis Elizabeth LLC brought a lawsuit against
      the FDA seeking to overturn the FDA's decision granting new chemical
      entity exclusivity to VYVANSE. Shire has intervened in the lawsuit. On
      October 23, 2009, following a period for public comment, the FDA issued
      a letter setting forth its analysis of the legal and regulatory issues
      and reaffirming its decision that VYVANSE is entitled to new chemical
      entity exclusivity. A hearing on cross-motions for summary judgment
      was held on February 17, 2010. No rulings on the cross-motions were made
      at the hearing.

    - On December 2, 2009 Shire announced that it had settled the litigation
      with Teva over Shire's supply to Teva of an authorized generic version
      of ADDERALL XR. Shire has been supplying Teva with authorized generic
      ADDERALL XR since April 1, 2009. Shire's ability to supply the product
      had been limited by restrictions that the US Drug Enforcement
      Administration ("DEA") places on amphetamine, which is the product's
      active ingredient. Teva filed suit claiming that Shire was in breach of
      its supply contract. After the lawsuit was filed, the DEA granted
      Shire additional quota for 2009, allowing Shire to supply Teva with
      additional product. Teva dismissed its lawsuit, including its claims for
      monetary damages, specific performance and other equitable relief. No
      consideration was exchanged by the parties as part of the settlement.

DIVIDEND

For the six months to December 31, 2009 the Board has resolved to pay an interim dividend of 9.250 US cents per ordinary share (2008: 7.761 US cents per ordinary share).

Dividend payments will be made in Pounds Sterling to ordinary shareholders and in US Dollars to holders of American Depository Shares. A dividend of 5.910 pence per ordinary share (2008: 5.469 pence) and 27.750 US cents per ADS (2008: 23.283 US cents) will be paid on April 14, 2010 to persons whose names appear on the register of members of the Company at the close of business on March 12, 2010.

Together with the first interim payment of 2.147 US cents per ordinary share (2008: 2.147 US cents per ordinary share), this represents total dividends for 2009 of 11.397 US cents per ordinary share (2008: 9.908 US cents per ordinary share), an increase of 15% in US Dollar terms over 2008.

BOARD CHANGES

On December 23, 2009 Dr Michael Rosenblatt stepped down from the Shire Board as a non-executive director, following Dr Rosenblatt's appointment as Executive Vice President and Chief Medical Officer at Merck & Co., Inc. Matt Emmens, Chairman of Shire said "On behalf of the Shire Board, I would like to thank Michael for his contributions and we wish him well in his new position".

Dr Barry Price retired from the Shire Board as a non-executive director upon the completion of his term of office on January 24, 2010. Matt Emmens, Chairman of Shire said "On behalf of the Shire Board, I would like to thank Barry for his significant contributions over the past 14 years. Barry brought a wealth of expertise and experience to the Board and we wish him well for the future".

    ADDITIONAL INFORMATION
    The following additional information is included in this press release:
                                                     Page
    Overview of Full Year Financial                   8
    Results
    Financial Information                             13
    Notes to Editors                                  27
    Safe Harbor Statement                             27
    Explanation of Non GAAP Measures                  27
    Trademarks                                        28

Dial in details for the live conference call for investors 14:00 GMT/09:00 EST on February 19, 2010:

    UK dial in:          0844-800-3850 or 01296-311-600
    US dial in:          1-866-8048688 or 1-718-3541175
    International dial   +44(0)1296-311-600
    in:
    Password/Conf ID:    587 261#
    Live Webcast:        http://www.shire.com/shireplc/en/investors

    OVERVIEW OF FULL YEAR FINANCIAL RESULTS
    1. Product sales

For the year to December 31, 2009 product sales decreased by 2% to $2,693.7 million (2008: $2,754.2 million) and represented 90% of total revenues (2008: 91%). On a CER basis product sales were flat compared to 2008.

Sales of core products increased by 25% to $2,067.2 million (2008: $1,652.5 million), up 28% on a CER basis.

    Product Highlights

                                                                    Exit
                                                                   Market
                                        Year on year growth       Share(1)
    Product              Sales $M    Sales       CER     US Rx(1)

    VYVANSE                 504.7      58%        58%        65%        13%
    ELAPRASE                353.1      16%        20%     n/a(3)     n/a(3)
    LIALDA / MEZAVANT       235.9      68%        69%        43%        18%
    PENTASA(R)              214.8      16%        16%        -2%        16%
    REPLAGAL                193.8      10%        16%     n/a(2)     n/a(2)
    FOSRENOL                184.4      19%        23%        -2%         8%
    FIRAZYR                   6.1   n/a(4)     n/a(4)     n/a(2)     n/a(2)
    INTUNIV                   5.4      n/a        n/a     n/a(2)         1%
    VPRIV(5)                  2.5      n/a        n/a     n/a(2)     n/a(2)
    OTHER                   366.5      -1%        n/a     n/a(2)     n/a(2)
    Core product sales    2,067.2      25%        28%
    ADDERALL XR             626.5     -43%       -43%       -42%         8%
    Total product sales   2,693.7      -2%         0%

(1) TRx data provided by IMS Health ("IMS") National Prescription Audit. Exit market share represents the US market share in the last week of December 2009.

    (2) Not sold in the US in 2009, or awaiting approval in the US.
    (3) IMS Data not available.
    (4) Product launched Q3 2008. FY 2008 sales totaled $0.5 million.
    (5) Not yet approved. Sales achieved under early access programs.
    Core Products
    VYVANSE - ADHD

The increase in VYVANSE product sales was driven by higher US prescription demand versus 2008, 9% growth in the US ADHD market and price increases. Product sales growth was lower than prescription growth due to lower stocking in 2009 compared to 2008.

ELAPRASE - Hunter syndrome

The growth in sales of ELAPRASE was driven by increased volumes across all regions where ELAPRASE is sold. On a CER basis sales grew by 20% (66% of ELAPRASE sales are made outside of the US).

LIALDA/MEZAVANT - Ulcerative colitis

Strong product sales of LIALDA/MEZAVANT continued in the year to December 31, 2009 driven by an increase in market share over 2008, growth in the US oral mesalamine market and price increases taken during 2009.

PENTASA - Ulcerative colitis

Product sales of PENTASA continued to grow despite a decrease in US prescription demand in 2009 compared to 2008 due to the impact of price increases taken during 2009.

REPLAGAL - Fabry disease

The growth in REPLAGAL product sales in 2009 over 2008 was driven by a significant increase in demand in the fourth quarter of 2009 due to an acceleration of patients switching to REPLAGAL in the EU, attributable in part to supply shortages of a competitor product. Sales increased 16% on a CER basis (REPLAGAL is sold primarily in Euros and Pounds sterling).

FOSRENOL - Hyperphosphatemia

Product sales increased as FOSRENOL entered new countries and grew in existing markets outside the US. In the US, FOSRENOL sales grew despite lower prescriptions due to a price increase in 2009.

INTUNIV - ADHD

INTUNIV was launched in the US in November 2009. In line with Shire's revenue recognition policy for launch shipments, initial stocking shipments have been deferred and are being recognised into revenue in line with end-user prescription demand. At December 31, 2009 deferred revenues on the balance sheet represented gross sales of $38.8 million.

Other products

ADDERALL XR - ADHD

The launch by Teva and Impax of their authorised generic versions of ADDERALL XR led to the expected decline in 2009 of branded ADDERALL XR prescription demand, and resulted in higher US sales deductions in 2009 compared to 2008. These factors more than offset the positive impacts of price increases taken since the fourth quarter of 2008, and the inclusion in product sales of shipments of authorized generic ADDERALL XR to Teva and Impax in 2009.

Sales deductions represented 47% of branded ADDERALL XR gross sales in the year to December 31, 2009 compared to 25% in the same period in 2008, following higher Medicaid and Managed Care rebates subsequent to the authorized generic launches.

There are potentially different interpretations as to how shipments of authorized generic ADDERALL XR to Teva and Impax should be included in the Medicaid rebate calculation pursuant to Medicaid rebate legislation, including the Deficit Reduction Act of 2005 ("Medicaid rebate legislation"). As a result more than one unit rebate amount ("URA") is calculable for the purpose of determining Shire's Medicaid rebate liability to States after the authorized generic launch. During 2009 Shire highlighted the different interpretations to the Centers for Medicare and Medicaid Services, ("CMS") and submitted data to the CMS for the purpose of computing the URA, based on Shire's reasonable interpretation of the Medicaid rebate legislation and related guidance. The State Medicaid agencies have invoiced Shire for Medicaid rebates, and Shire has paid these Medicaid rebate invoices, based on this URA. Despite this CMS has the ability to subsequently challenge Shire's interpretation of the Medicaid rebate legislation, and require an alternative interpretation to be applied (both retrospectively and prospectively), which could result in a significantly higher Medicaid liability.

Throughout 2009 Shire's management has recorded its accrual for Medicaid rebates based on its best estimate of the rebate payable. For the first three quarters of 2009, Shire's management based this best estimate on an amount that Shire could pay were CMS to challenge Shire's interpretation and require an alternative interpretation of the Medicaid rebate legislation to be applied. In the fourth quarter of 2009, Shire's management lowered its best estimate of the Medicaid rebate payable down to be consistent with (i) Shire's interpretation of the Medicaid rebate legislation, (ii) Shire's repeated and consistent submission of price reporting to CMS using Shire's interpretation of the Medicaid rebate legislation, (iii) CMS calculating the URA based on that interpretation, (iv) States submitting Medicaid rebate invoices using this URA, and (v) Shire paying these invoices. This change of estimate increased ADDERALL XR product sales by $97.7 million in the fourth quarter of 2009 (of which $73.6 million related to ADDERALL XR product sales recognized in Q1-Q3 2009).

In determining its best estimate of the Medicaid rebate liability at December 31, 2009 Shire's management has considered a number of factors taken in combination (including the receipt of a further quarter's invoices from the States with a URA based on Shire's interpretation of the Medicaid rebate legislation and related guidance, and Shire's likely response were CMS to employ an alternative interpretation of the Medicaid rebate legislation). Any future change in Shire's interpretation which results in a change of estimate could significantly decrease sales of ADDERALL XR in the period of any such change in estimate.

Shire strongly believes that its interpretation of the Medicaid rebate legislation is reasonable and correct. However, CMS could disagree with Shire's interpretation, and require Shire to apply an alternative interpretation of the Medicaid rebate legislation and pay up to $210 million above the recorded liability. This would represent a URA substantially in excess of the unit sales price of ADDERALL XR and accordingly be in excess of the approximate amount of the full cost to the States of reimbursement for Medicaid prescriptions of ADDERALL XR. Should CMS take such an approach, Shire could seek to limit any additional payments to a level approximating the full, un-rebated cost to the States of ADDERALL XR, or $98 million above the recorded liability. Further, Shire believes it has a strong legal basis supporting its interpretation of the Medicaid rebate legislation, and that there would be a strong basis to initiate litigation to recover any amount paid in excess of its recorded liability. The result of any such litigation cannot be predicted and could result in additional rebate liability above Shire's current best estimate.

    2. Royalties

    Product              Royalties to Shire $M  Year on year change  CER
    3TC(R) and Zeffix(R)          164.0                 -9%          -6%
    ADDERALL XR                    68.0                 n/a          n/a
    Other                          60.5                 -7%          -3%
    Total                         292.5                +19%          +22%

Shire receives royalties from GlaxoSmithKline ("GSK") on worldwide sales of 3TC and ZEFFIX which have decreased mainly due to competition from other treatments.

Royalties were received on Teva's sales of an authorized generic version of ADDERALL XR between April and September 2009, and on Impax's sales of its authorized generic version of ADDERALL XR from October 2009.

Other royalties are received primarily on worldwide (excluding UK and Republic of Ireland) sales of REMINYL(R) and REMINYL(R) XL (known as RAZADYNE(R) and RAZADYNE(R) ER in the US). Royalties on sales of these products decreased in 2009 to $47.7 million (2008: $63.5 million) due to generic competition in the US from August 2008.

    3. Financial details
    Cost of product sales


                                                % of                 % of
                                   2009        product   2008       product
                                     $M        sales       $M        sales

    Cost of product sales         388.0          14%    408.0         15%
    Accelerated depreciation on
    transfer of manufacturing
    from Owings Mills            (12.0)                     -
    Fair value adjustment for
    acquired inventories          (1.9)                     -
    DYNEPO exit costs                 -                (48.8)
    Depreciation                  (9.8)                (16.2)
    Non GAAP cost of product      364.3          14%    343.0         12%
    sales

Non GAAP cost of product sales as a percentage of product sales increased in 2009 due to changes to the product mix following the launch of authorized generic versions of ADDERALL XR by Teva and Impax. Higher deductions on Shire's sales of branded ADDERALL XR, together with lower margins on sales of the authorized generic version to Teva and Impax have both depressed gross margins.

    Research and development ("R&D")

                                                % of                 % of
                                   2009        product   2008       product
                                     $M        sales       $M        sales

    R&D                           638.3          24%    494.3          18%
    INTUNIV license payment       (36.9)                    -
    Women's Health exit costs     (62.9)                    -
    DYNEPO exit costs                 -                  (6.5)
    Depreciation                  (15.5)                (12.5)
    Non GAAP R&D                  523.0          19%    475.3          17%

Non GAAP R&D increased 10% in 2009 compared to 2008 as Shire has continued to increase investment in R&D programs, due in part to an acceleration of investment in VPRIV and REPLAGAL in the US.

    Selling, general and administrative ("SG&A")

                                               % of                 % of
                                   2009        product   2008       product
                                     $M        sales       $M        sales
    SG&A                        1,342.6         50%   1,455.2        53%
    Intangible asset             (136.9)               (126.2)
    amortization
    Impairment of intangible          -                 (97.1)
    assets
    New holding company costs         -                 (14.8)
    Depreciation                  (67.7)                (48.5)
    Non GAAP SG&A               1,138.0         42%   1,168.6        42%

Non GAAP SG&A decreased in absolute terms by 3% due to Shire's continued focus on cost management.

Gain on sale of product rights

For the year to December 31, 2009 Shire recorded gains of $6.3 million (2008: $20.7 million) from the sale of non-core products to Laboratorios Almirall S.A. in 2007. These gains had been deferred since 2007 pending obtaining the relevant consents to transfer certain assets.

IPR&D

For the year to December 31, 2009, Shire recorded IPR&D charges of $1.6 million (2008: $128.1 million) relating to FIRAZYR in markets outside of the EU. In 2008 IPR&D also included a charge of $135.0 million relating to the acquisition of METAZYM from Zymenex A/S.

Reorganization costs

For the year to December 31, 2009 Shire recorded reorganization costs of $12.7 million (2008: $nil) relating to the transfer of manufacturing from its Owings Mills facility.

Integration and acquisition costs

For the year to December 31, 2009 Shire recorded integration and acquisition costs of $10.6 million (2008: $10.3 million), primarily relating to the integration of Jerini.

Interest income

For the year to December 31, 2009 Shire received interest income of $1.9 million (2008: $25.5 million), primarily earned on cash and cash equivalents. Interest income for the year to December 31, 2009 is lower than the same period in 2008 due to significantly lower interest rates in 2009 compared to 2008, and lower average cash and cash equivalent balances throughout the year.

    Interest expense

                                                                 2009    2008
                                                                   $M      $M
    Interest expense                                             39.8   139.0
    Additional interest on settlement of TKT appraisal rights       -  (73.0)
    litigation
    Non GAAP interest expense                                    39.8    66.0

For the year to December 31, 2009 Shire incurred interest expense of $39.8 million (2008: $139.0 million), including interest expense on Shire's convertible bond of $33.6 million (2008: $33.6 million). Interest expense in 2008 was higher than 2009 due to interest expense of $87.3 million recorded in respect of the TKT appraisal rights litigation, of which $73.0 million was additional interest arising from the settlement of the litigation in November 2008.

    Other income/(expense), net

                                                                 2009    2008
                                                                   $M      $M
    Other income/(expense), net                                  60.7  (32.9)
    Gain on sale of investment in Virochem Pharma Inc.         (55.2)       -
    Gain on sale of investment in Questcor Pharmaceuticals Inc.     -   (9.4)
    Other than temporary impairment of available for sale
    securities (including $44.3 million for Renovo Group plc)       -    58.0
    Non GAAP other income, net                                    5.5    15.7

Non GAAP other income, net in 2009 included a gain of $5.7 million on substantial modification of a property lease. In 2008 Non GAAP other income, net primarily related to foreign exchange gains.

Taxation

The effective rate of tax for the year to December 31, 2009 was 22% (2008: 37%). Excluding the impact of IPR&D charges of $263.1 million in 2008, which are either not tax deductable or for which no tax benefit is currently recognised, the effective rate of tax for 2008 was 19%. The effective tax rate on Non GAAP income is 25% (2008: 23%).

The Non GAAP effective rate of tax in 2009 is higher than 2008 due to increased profits in higher tax territories, together with the recognition of valuation allowances against certain EU and US deferred tax assets. These factors more than offset reductions to the Non GAAP effective rate of tax from the decrease in valuation allowances held in respect of US State tax credits and losses. In addition, the effect of the change in best estimate of ADDERALL XR Medicaid rebates increased the Non GAAP effective rate of tax by one percentage point in 2009.

Discontinued operations

The loss from discontinued operations for the year to December 31, 2009 was $12.4 million (2008: $17.6 million), relating to net losses on discontinued Jerini businesses which were either divested or closed during 2009.

    FINANCIAL INFORMATION
    TABLE OF CONTENTS

                                                          Page

    Unaudited US GAAP Statement of Financial Position       14
    Unaudited US GAAP Consolidated Statements of
    Operations                                              15
    Unaudited US GAAP Consolidated Statements of Cash
    Flows                                                   17
    Selected Notes to the Unaudited US GAAP Financial
    Statements
    (1) Earnings per share                                  19
    (2) Analysis of revenues                                20
    Non GAAP reconciliation                                 22


    Unaudited US GAAP financial position as of December 31, 2009 Consolidated
Balance Sheets

                                                                 Restated(1)
                                                   December 31, December 31,
                                                           2009         2008
                                                             $M           $M
    ASSETS
    Current assets:
    Cash and cash equivalents                             498.9        218.2
    Restricted cash                                        33.1         29.2
    Accounts receivable, net                              597.5        395.0
    Inventories                                           189.7        154.5
    Assets held for sale                                    1.7         16.6
    Deferred tax asset                                    135.8         89.5
    Prepaid expenses and other current assets             113.5        141.4

    Total current assets                                1,570.2      1,044.4

    Non-current assets:
    Investments                                           105.7         42.9
    Property, plant and equipment, net                    676.8        534.2
    Goodwill                                              384.7        350.8
    Other intangible assets, net                        1,790.7      1,824.9
    Deferred tax asset                                     79.0        118.1
    Other non-current assets                               10.4         18.4

    Total assets                                        4,617.5      3,933.7

    LIABILITIES AND EQUITY
    Current liabilities:
    Accounts payable and accrued expenses                 929.1        708.6
    Deferred tax liability                                  2.9         10.9
    Other current liabilities                              88.0        104.3
     Total current liabilities                          1,020.0        823.8

    Non-current liabilities:
    Convertible bonds                                   1,100.0      1,100.0
    Other long-term debt                                   43.6         43.1
    Deferred tax liability                                294.3        348.0
    Other non-current liabilities                         247.1        291.3

    Total liabilities                                   2,705.0      2,606.2

    Shareholders' equity:
    Common stock of 5p par value; 1,000 million
    shares authorized; and 561.5 million shares
    issued and outstanding (2008: 1,000 million
    shares authorized; and 560.2 million shares
    issued and outstanding)                                55.6         55.5
    Additional paid-in capital                          2,677.6      2,594.6
    Treasury stock: 17.8 million shares (2008: 20.7
    million)                                             (347.4)      (397.2)
    Accumulated other comprehensive income                149.1         97.0
    Accumulated deficit                                  (622.4)    (1,022.7)

    Total Shire plc shareholders' equity                1,912.5      1,327.2
    Noncontrolling interest in subsidiaries                   -          0.3

    Total equity                                        1,912.5      1,327.5

    Total liabilities and equity                        4,617.5      3,933.7

    (1) See page 28 for details.

Unaudited US GAAP results for the three months and year to December 31, 2009 Consolidated Statements of Operations

                                                      12 months    12 months
                           3 months to  3 months to         to         to
                           December 31, December 31, December 31, December 31
                                  2009         2008         2009         2008
                                    $M           $M           $M           $M
    Revenues:
    Product sales                776.9        704.3      2,693.7      2,754.2
    Royalties                    114.7         54.8        292.5        245.5
    Other revenues                 1.7          6.7         21.5         22.5
    Total revenues               893.3        765.8      3,007.7      3,022.2

    Costs and expenses:
    Cost of product sales(1)     103.1         90.6        388.0        408.0
    Research and
    development(2)               145.8        125.9        638.3
'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Shire Continues to Deliver Excellent Growth From Core Products
2. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
3. Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest
4. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
5. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
6. New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability
7. Research Shows VASER(R) Lipo Results in Excellent Skin Tightening
8. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
9. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
10. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
11. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... India , May 4, 2016 ... spreads across 154 pages, profiling 09 key companies ... is a professional and in-depth study on the ... a basic overview of the industry including definitions, ... Needles market analysis is provided for the international ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
Breaking Medicine Technology:
(Date:5/4/2016)... Ventura, CA (PRWEB) , ... May 04, 2016 , ... ... cutting-edge technology to help restore its patients’ health, is hosting a free seminar on ... and will be held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, ...
(Date:5/4/2016)... ... 2016 , ... AudioEducator is the country's top training providers ... has lined up some informative training session for the medical coding and billing ... and practical, easy-to-apply advice. , On Thursday, May 19, AudioEducator will host a ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and elbows. Engineered with athletes in mind, OMNIFORCE offers high-performance, less bulk, ... circular knitting, common in the industry) produces premium flat-knit construction with “focused ...
(Date:5/4/2016)... City, Nevada (PRWEB) , ... May 04, 2016 , ... ... bladder infections. Bladder infections, also called UTIs, have plagued people since the beginning ... millions of women get bladder infections every year. It's not just a matter of ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May ... and child products, today revealed the non-toxic benefits of its Tutti ... deal with teething pain is just part of the story. These ... are BPA-, PVC-, and phthalate-free. , “Many baby toys contain ...
Breaking Medicine News(10 mins):